Document Certificate
Owner:
Martin Wong
Number:
HK-NOTPR-0004
Name:
AsCNP 2019 - FUNCTIONAL RECOVERY V1
Category:
Promotional Piece
We hereby certify that we have examined the final form of the material and in our belief it is in
accordance with the requirements of the local law and regulations, is consistent with the marketing
authorisation and the SPC, and is a fair and truthful representation of the facts about the medicine.
Document Approvals
Approval
Lydia Ho
Approver
30-Dec-2019 02:31:17 GMT+0000
Approval
Viviendouf Yin Wei Koh
Marketing Approver
30-Dec-2019 02:44:35 GMT+0000
Approval
Lynette Wong
Regulatory Approver
02-Jan-2020 01:43:45 GMT+0000
Approval
Keira Joann Herr
Regulatory Approver
02-Jan-2020 02:11:00 GMT+0000
Approval
Lars Nelleman
Medical Approver
03-Jan-2020 06:31:36 GMT+0000
DEPRESSION SATELLITE SYMPOSIUM
From response and remission to full functional recovery in
major depressive disorder: Is patient-involvement the
missing link?
Depression is a common and serious illness with heterogeneous
symptoms within emotional, physical and cognitive domains.
Although a wide range of approved drugs for treating major
depression are available, a considerable proportion of patients who
meet formal criteria for remission do not consider themselves in
remission, or do not obtain functional recovery. In this symposium,
three experts gave their view on limitations in our current approach to
treatment selection and treatment goals, and offered future directions
for optimizing the treatment of depression.
By Prof. Roger McIntype, Prof. Bernhard Baune and Prof. Stephen Stahl
Scan to read now
Looking beyond the ‘average’ patient: A neuroscientific approach to targeting individual
patient profiles
Stephen Stahl, Professor at the University of California San Diego, USA, opened the symposium
explaining that clinical guidelines for the treatment of depression are based on meta-analyses
typically concluding that different antidepressants are equally efficacious. 1 Meta-analyses,
however, Prof Stahl noted, reflect what works for the ‘average’ patient; yet many patients’
symptom profiles do not represent the ‘average’ patient. Highlighting the heterogeneity of
symptoms in depression, spanning from loss of interest and fatigue to concentration problems
and impaired psychomotor function, he pointed out that different pharmacological agents with
different specific targets may impact on different clinical measures across the range of symptom
domains. Therefore, Prof Stahl noted, we should consider the specific mechanisms of an agent
relative to the symptom profile to be able to select the right treatment for the individual patient as
early as possible.
Meta-analyses reflect what works for the ‘average’
patient but many patients’ symptom profiles do
not represent the ‘average’ patient.
Highlighting persistent cognitive impairment as a common and debilitating symptom in
depression,2 Prof Stahl explained that while monoaminergic agents target mainly brain circuits
regulating mood symptoms, multiple neurotransmitter systems are involved in cognition, including
cholinergic, dopaminergic, norepinephrinergic, histaminergic, GABAergic, and glutamatergic
pathways.3,4 Therefore, Prof Stahl noted, we should consider the specific mechanisms of an
agent relative to the symptom profile to be able to select the right treatment for the individual
patient as early as possible.
Closing the gap between patient and clinician perceptions to improve treatment outcomes
The next speaker, Bernhard Baune, Professor at the University of Münster, Germany, pointed
out the apparent paradoxes that more than half of patients who meet ……………
REFERENCES :
1. Cipriani A et al. Lancet 2018; 391: 1357–1366.
2. Zimmerman M, et al. J Clin Psychiatry. 2012;73(6):790–95
3. Papakostas GI. Am J Manag Care 2009; 15: S316-S321
4. Baune BT, Christensen MC. Front Psychiatry 2019; 10: 335.
If you would like to continue reading this article, please visit http://SEA.PROGRESS.IM
Brought to you by
HK-PIM-2019.12-LB02-LUHK